同义名 :	优地那非 ;DA8159
	CAS号 :	268203-93-6
	货号 :	A444987
	分子式 :	C25H36N6O4S
	纯度 :	98%
	分子量 :	516.66
	MDL号 :	MFCD20275557
	存储条件：	Pure form Inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Udenafil is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor[3]. Udenafil is as effective in the treatment of diabetes mellitus-associated ED (Erectile dysfunction) as other PDE5Is[4]. Subcutaneous injection of udenafiltreated ASCs (adipose-derived stem cells) accelerated telogen-to-anagen transition in vivo. Udenafil stimulates ASC motility and increases paracrine growth factor, including cytokine signaling. Udenafil-stimulated secretion of cytokine from ASCs may promote hair growth via the ERK and NFκB pathways[5]. Udenafil has a better renoprotective effect than mannitol against I/R (ischemia-reperfusion) injury and this effect supports more functional improvements[6]. Udenafil inhibited the survival and growth of VEC (vascular endothelial cell) and VSMC (vascular smooth muscle cell) in a concentration-dependent manner over a range of concentrations. At 100 μM, udenafil, inhibited VEC proliferation significantly less than VSMC proliferation, and could significantly induce VEC apoptosis less than VSMC apoptosis[7].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00767598	Pharmacokinetics of Three PDE5... 展开 >>Is Healthy Subjects Genetic Polymorphic CYP3A5 收起 <<	Phase 1	Completed	-	-
NCT03430583	-		Recruiting	December 31, 2020	-
NCT01232010	Renal Insufficiency ... 展开 >> Kidney Diseases Urologic Diseases 收起 <<	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of 收起 <<

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	1.94mL 0.39mL 0.19mL	9.68mL 1.94mL 0.97mL	19.36mL 3.87mL 1.94mL

参考文献

[1]Zhao C, Kim SH, et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011 Jun;107(12):1943-7. [2]Paick JS, Kim SW, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008 Apr;5(4):946-53. [3]Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh JK, Kim SC. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008 Apr;5(4):946-953 [4]Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014 May 14;10:341-54 [5]Choi N, Sung JH. Udenafil Induces the Hair Growth Effect of Adipose-Derived Stem Cells. Biomol Ther (Seoul). 2019 Jul 1;27(4):404-413 [6]Özlülerden Y, Toktaş C, Aybek H, Küçükatay V, Şen Türk N, Zumrutbas AE. The renoprotective effects of mannitol and udenafil in renal ischemia-reperfusion injury model. Investig Clin Urol. 2017 Jul;58(4):289-295 [7]Fang CH, Song YS, So BI, Kim H, Shin JH, Kim KS. Concentration-dependent differential effects of udenafil on viability, proliferation, and apoptosis in vascular endothelial and smooth muscle cells. Indian J Pharmacol. 2014 May-Jun;46(3):292-7